Please login to the form below

Not currently logged in
Email:
Password:

Astellas names Linda Friedman as EVP, general counsel

She is due to take up the role on 1 April

Astellas Linda FriedmanAstellas has appointed Linda Friedman as executive vice president, general counsel with responsibility for the company's legal organisation worldwide.

She is set to take up the post from 1 April this year, and will report to Astellas' president and chief executive officer Yoshihiko Hatanaka.

Friedman currently serves as senior vice president and general counsel for Astellas Americas, having first joined Fujisawa in 1993 as a corporate attorney prior to its merger with Yamanouchi.

Since then, Friedman has held positions of increasing responsibility, including senior corporate counsel and vice president for Astellas' US operations and subsequently the Americas region.

She is chair of the board of director at the iBIO Institute, and a member of the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Healthcare Business Women's Association (HBA).

Hatanaka said: “For nearly 24 years, Linda has played a formative role in the evolution of Astellas.

“Linda's role will help develop a new model for our legal team, allowing us to better serve our global and regional business while focusing on the needs of patients worldwide.”

16th February 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Patient journey mapping: exploring the clinical and the emotional journey
By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew While we can all agree that the value of developing a patient journey map cannot be underestimated when exploring the...
Precision medicine at Blue Latitude Health
At Blue Latitude Health we have identified 90+ insights about commercialising precision medicines. Check out our video to get a run down on three core components of the commercialisation and...
Understanding the evolving CAR-T market
In 2017 the approval of the first CAR-T treatment took the world by storm, transforming the way cancer is treated, but two years later more than 500 CAR-Ts are in...

Infographics